Hirata Y, Kurobe H, Nishio C, Tanaka K, Fukuda D, Uematsu E, Nishimoto S, Soeki T, Harada N, Sakaue H
Let me ask a big picture question to end our conversation
Genevas physicians help patients determine whether Tirzepatides dual pathway activity is the best fit for their metabolic needs and comfort level
The off-label application without specific FDA approval for non-diabetic patients raises regulatory and safety concerns
Yazhou Li, a neuroscientist at the National Institute of Aging in Bethesda, Maryland, studies the effects of different drugs on brain impairments including traumatic brain injury, Alzheimers disease, stroke, and Parkinsons disease
Thyroid antibodies: which, why, when and who